GT Biopharma, Inc. filed Certificates of Elimination to remove all outstanding series of preferred stock from its Charter and a Certificate of Amendment to effect a 1-for-25 reverse stock split of its common stock effective September 8, 2026. The split reduces issued shares from approximately 45.1 million to roughly 1.8 million and lowers authorized capital stock from 265 million to 26.5 million shares. This action follows shareholder approval at the August 14, 2026 annual meeting. GT Biopharma operates in the biotechnology industry, focusing on developing immunotherapies for cancer treatment.

GT Biopharma, Inc. held its Annual Meeting of Stockholders on August 14, 2026, where shareholders approved several key proposals. The meeting resulted in the election of four directors: Michael Breen, Charles J. Casamento, Hilary Kramer, and David C. Mun-Gavin. Shareholders also ratified Weinberg & Company, P.A. as independent accountants and approved a non-binding advisory vote on executive compensation. Significantly, stockholders authorized an amendment to the restated certificate of incorporation to permit a reverse stock split at a ratio between 1-for-10 and 1-for-30, alongside a reduction in authorized common shares to 25,000,000 and preferred shares to 1,500,000. The Board retains discretion to determine the specific split ratio and effective date within one year. Additionally, shareholders approved an increase of 3,500,000 shares in the 2022 Omnibus Incentive Plan and adopted an evergreen provision for automatic annual increases. GT Biopharma operates as a clinical-stage biotechnology company focused on developing immunotherapies.

GT Biopharma, Inc. amended its bylaws-to-reduce the quorum requirement for stockholder-to-meetings. The Board of Directors approved an amendment effective June 8, 2026, which reduced the holders of not less than one-third (1/3) of outstanding shares to constitute a quorum. This change was implemented to address difficulty in obtaining a majority quorum due to brokerage firms opting to forgo discretionary voting of shares held in street name. GT Biopharma, Inc. is a biotechnology company focused on research and development of biological products.